Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: Results from the 2001-2002 National Health and Nutrition Examination Survey

Cancer

Volumn 113, Issue 8, 2008, Pages 2053-2057

  Singer, Eric A ^a   Palapattu, Ganesh S ^a   Van Wijngaarden, Edwin ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Acetaminophen; Epidemiology; Inflammation; Nonsteroidal anti inflammatory drug; Prostate specific antigen

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG USE; EDUCATIONAL STATUS; GENITAL INJURY; HEALTH SURVEY; HEART DISEASE; HUMAN; INFLAMMATORY DISEASE; INJURY; LINEAR REGRESSION ANALYSIS; MALE; NUTRITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PUBLIC HEALTH; RACE; RISK REDUCTION; SMOKING;

ACETAMINOPHEN; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 55749084365     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23806     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 suppl):2371-2490.
3. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am. 2003;30:209-217.
4. Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ. 1998;159:807-813.
5. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-864.
6. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13.
7. Levy IG, Iscoe NA, Klotz LH. Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ. 1998;159:509-513.
8. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc. 2005;80:899-907.
9. Signorello LB, Adami HO. Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Textbook of Cancer Epidemiology. New York: Oxford University Press; 2002:400-428.
10. Stotts RC. Cancers of the prostate, penis, and testicles: epidemiology, prevention, and treatment. Nurs Clin North Am. 2004;39:327-340.
11. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-1413.
12. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381.
13. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem. 2004;91:459-477.
14. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:S36-S40.
15. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-269.
16. National Center for Health Statistics. NHANES 2001-2002 data files. Vol. 2005. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2005.
17. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97:1132-1137.
18. Saraiya M, Kottiri BJ, Leadbetter S, et al. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev. 2005;14:2178-2182.
19. Lam JS, Cooper KL, Kaplan SA. Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia. Med Clin North Am. 2004;88:281-308.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
21. Pruthi RS, Kouba E, Carson CC III, Mullen EC. Cyclooxygenast-2 inhibitors and other NSAIDs in urology: current peril or future promise? Urology. 2006;68:917-923.
22. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557-561.
23. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000;56:671-676.
24. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53:232-240.
25. Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S, Campell WB. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis. 2002;19:593-601.
26. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res. 2005;11:3250-3256.
27. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926-13931.
28. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther. 2005;315:1-7.
29. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22:383-390.
30. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004;90:93-99.
31. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of nonselective COX-2 blockade [review]. Oncol Rep. 2005;13:559-583.
32. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99:608-615.
33. Platz EA, Rohrmann S, Pearson JD, et al. Nonsteroidal antiinflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev. 2005;14:390-396.
34. Chan JM, Feraco A, Shuman M, Hernandez-Diaz S. The epidemiology of prostate cancer - with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am. 2006;20:797-809.
35. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007;178(3 pt 2):S9-S13.